Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8863
  • E-ISSN: 2212-3911

Abstract

Background

Hyperprolactinemia is a commonly underestimated adverse effect of antipsychotic medications. There are still no consensus guidelines for the optimal monitoring and treatment strategies.

Objective

The aim of the study was to assess the monitoring and treatment practices of antipsychotic-induced hyperprolactinemia, in addition to the prevalence and risk factors associated with it.

Methods

A retrospective cohort observational study was conducted among patients attending the psychiatric clinics at an academic tertiary hospital in Riyadh, Saudi Arabia, from May 2020 until May 2021, by reviewing each patient’s medical record for up to five years.

Results

Among the 662 patients, 35 patients (5.3%) and 242 patients (36.6%) had their serum prolactin levels monitored (at baseline and at follow-up, respectively). The prevalence of hyperprolactinemia was observed in 212 patients (32%). Only 76 patients (36%) were symptomatic. Female gender, younger age, and bipolar disorder had a significantly higher risk of developing hyperprolactinemia. 60% of the confirmed cases received treatment, of which 76 (60%) were adherent to treatment guidelines. The most common treatment strategies implemented were dose reduction (42.5%) and aripiprazole augmentation (29.1%).

Conclusion

It is imperative to conduct a baseline check of prolactin levels before commencing any antipsychotic therapy. Similarly, routine prolactin level monitoring is recommended regardless of symptoms in patients treated with antipsychotics with a possible prolactin-raising effect. Adherence to evidence-based treatment guidelines can improve patient quality of life and therapeutic compliance.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863280407240305070905
2025-05-01
2025-09-02

  • From This Site

    /content/journals/cds/10.2174/0115748863280407240305070905
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PeuskensJ. PaniL. DetrauxJ. De HertM. The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review.CNS Drugs201428542145310.1007/s40263‑014‑0157‑3 24677189
     [Google Scholar]
  2. AlosaimiF.D. FallataE.O. AbalhassanM. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications.Int. J. Psychiatry Clin. Pract.201822427428110.1080/13651501.2018.1425459 29334291
     [Google Scholar]
  3. ByerlyM. SuppesT. TranQ.V. BakerR.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: Recent developments and current perspectives.J. Clin. Psychopharmacol.200727663966110.1097/jcp.0b013e31815ac4e5 18004132
     [Google Scholar]
  4. GuptaS. LakshmananD.A.M. KhastgirU. NairR. Management of antipsychotic-induced hyperprolactinaemia.BJ Psych Adv.201723427828610.1192/apt.bp.115.014928
     [Google Scholar]
  5. TorreD.L. FalorniA. Pharmacological causes of hyperprolactinemia.Ther. Clin. Risk Manag.200735929951 18473017
     [Google Scholar]
  6. MelmedS. CasanuevaF.F. HoffmanA.R. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline.J. Clin. Endocrinol. Metab.201196227328810.1210/jc.2010‑1692 21296991
     [Google Scholar]
  7. MontejoÁ.L. ArangoC. BernardoM. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics.Front. Neuroendocrinol.201745253410.1016/j.yfrne.2017.02.003 28235557
     [Google Scholar]
  8. TewksburyA. OlanderA. Management of antipsychotic-induced hyperprolactinemia.Ment. Health Clin.20166418519010.9740/mhc.2016.07.185 29955468
     [Google Scholar]
  9. BostwickJ.R. GuthrieS.K. EllingrodV.L. Antipsychotic‐induced hyperprolactinemia.Pharmacotherapy2009291647310.1592/phco.29.1.64 19113797
     [Google Scholar]
  10. NICEPsychosis and schizophrenia in adults: Prevention and management. https://www.nice.org.uk/guidance/cg178
  11. HoltR.I.G. PevelerR.C. Antipsychotics and hyperprolactinaemia: Mechanisms, consequences and management.Clin. Endocrinol.201174214114710.1111/j.1365‑2265.2010.03814.x 20455888
     [Google Scholar]
  12. PevelerR.C. BranfordD. CitromeL. Antipsychotics and hyperprolactinaemia: Clinical recommendations.J. Psychopharmacol.200822S29810310.1177/0269881107087346 18477626
     [Google Scholar]
  13. WaltersJ. JonesI. Clinical questions and uncertainty — Prolactin measurement in patients with schizophrenia and bipolar disorder.J. Psychopharmacol.200822S2828910.1177/0269881107086516 18477624
     [Google Scholar]
  14. SerriO. ChikC.L. UrE. EzzatS. Diagnosis and management of hyperprolactinemia.Can. Med. Assoc. J.20031696575581
     [Google Scholar]
  15. VilarL. FleseriuM. BronsteinM.D. Challenges and pitfalls in the diagnosis of hyperprolactinemia.Arq. Bras. Endocrinol. Metabol201458192210.1590/0004‑2730000003002 24728159
     [Google Scholar]
  16. KinonB.J. GilmoreJ.A. LiuH. HalbreichU.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone11This work was sponsored by Eli Lilly and Company.Psychoneuroendocrinology200328S2556810.1016/S0306‑4530(02)00127‑0 12650681
     [Google Scholar]
  17. DeheleanL. RomosanA.M. PapavaI. Prolactin response to antipsychotics: An inpatient study.PLoS One2020152e022864810.1371/journal.pone.0228648 32017792
     [Google Scholar]
  18. AlhussainH. AldayelA.A. AlenaziA. AlowainF. Multiple sclerosis patients in Saudi Arabia: Prevalence of depression and its extent of severity.Cureus2020122e700510.7759/cureus.7005 32206469
     [Google Scholar]
  19. MontejoÁ.L. MajadasS. VillademorosR.F. Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.J. Sex. Med.20107103404341310.1111/j.1743‑6109.2010.01709.x 20214720
     [Google Scholar]
  20. CorrellC.U. CarlsonH. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.J. Am. Acad. Child Adolesc. Psychiatry200645777179110.1097/01.chi.0000220851.94392.30 16832314
     [Google Scholar]
  21. GudelskyG.A. NanselD.D. PorterJ.C. Role of estrogen in the dopaminergic control of prolactin secretion.Endocrinology1981108244044410.1210/endo‑108‑2‑440 7449733
     [Google Scholar]
  22. InderW.J. CastleD. Antipsychotic-induced hyperprolactinaemia.Aust. N. Z. J. Psychiatry2011451083083710.3109/00048674.2011.589044 21714721
     [Google Scholar]
  23. RodríguezG.A. GuàrdiaA. PedreroA.A. Women with schizophrenia over the life Span: Health promotion, treatment and outcomes.Int. J. Environ. Res. Public Health20201715559410.3390/ijerph17155594 32756418
     [Google Scholar]
  24. RusgisM.M. AlabbasiA.Y. NelsonL.A. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.Am. J. Health Syst. Pharm.2021781086287110.1093/ajhp/zxab065 33954421
     [Google Scholar]
  25. DorovskikhV. PavlovaA. ScheideggerM. Cariprazine is a modern antipsychotic with a favorable neuroendocrine profile.Biomed. Sci.202023586310.17816/phf46072
     [Google Scholar]
  26. MulderR. HamiltonA. IrwinL. BoyceP. MorrisG. PorterR. Treating depression with adjunctive antipsychotics.Bipolar Disord.201820S2172410.1111/bdi.12701
     [Google Scholar]
  27. LertxundiN. MolinueveA. ValviD. GorostiagaA. BalluerkaN. ShirappaN. Dietary inflammatory index of mothers during preganacy and attention deficit-hyperactivity disorder systems in the child at preschool age: A prospective investigation in the INMA and RHEA cohorts.Eur. Child Adolesc. Psychiatry2021314615624
     [Google Scholar]
  28. BudayrA. TanT.C. LoJ.C. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: The CATCH study.BMC Endocr. Disord.20202012510.1186/s12902‑020‑0507‑8 32075620
     [Google Scholar]
  29. ChenC.K. HuangY.S. ReeS.C. HsiaoC.C. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.Prog. Neuropsychopharmacol. Biol. Psychiatry20103481495149910.1016/j.pnpbp.2010.08.012 20732372
     [Google Scholar]
  30. ZhuoC. XuY. WangH. FangT. ChenJ. ZhouC. Safety and efficacy of high-dose vitamin B6 as an adjunctive treatment for antipsychotic-induced hyperprolactinemia in male patients with treatment-resistant schizophrenia.Sec Psychopharmacol20211211110.3389/fpsyt.2021.681418
     [Google Scholar]
  31. WuH. DengL. ZhaoL. ZhaoJ. LiL. ChenJ. Osteoporosis associated with antipsychotic treatment in schizophrenia.Int. J. Endocrinol.201320131710.1155/2013/167138 23690768
     [Google Scholar]
/content/journals/cds/10.2174/0115748863280407240305070905
Loading
Assessment of Monitoring and Management Practices of Antipsychotic-Induced Hyperprolactinemia at a Medical City in Riyadh, Saudi Arabia: A Retrospective Cohort Study
Curr Drug Saf 20, 214 (2025); https://doi.org/10.2174/0115748863280407240305070905
/content/journals/cds/10.2174/0115748863280407240305070905
/content/journals/cds/10.2174/0115748863280407240305070905
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): amenorrhea; Antipsychotics; dopamine (D2); hyperprolactinemia; prolactin; sexual dysfunction

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test